ChromaDex Co. (NASDAQ:CDXC) Short Interest Down 7.5% in October

ChromaDex Co. (NASDAQ:CDXC) saw a significant drop in short interest in October. As of October 15th, there was short interest totalling 2,960,000 shares, a drop of 7.5% from the September 30th total of 3,200,000 shares. Currently, 6.2% of the company’s stock are sold short. Based on an average trading volume of 264,700 shares, the short-interest ratio is presently 11.2 days.

Insider Activity at ChromaDex

In other ChromaDex news, Director Kristin Patrick sold 23,000 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $3.57, for a total transaction of $82,110.00. The sale was disclosed in a filing with the SEC, which is available through this link. 9.64% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC grew its stake in shares of ChromaDex by 8.4% during the 2nd quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock valued at $1,136,000 after purchasing an additional 32,400 shares during the period. WINTON GROUP Ltd purchased a new position in shares of ChromaDex in the second quarter worth approximately $597,000. Bank of New York Mellon Corp grew its position in ChromaDex by 170.0% during the second quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock valued at $520,000 after buying an additional 119,915 shares during the period. BSW Wealth Partners purchased a new stake in ChromaDex during the third quarter valued at approximately $324,000. Finally, Rhumbline Advisers bought a new position in ChromaDex in the second quarter worth approximately $124,000. Institutional investors own 15.41% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of ChromaDex in a report on Friday, August 9th.

ChromaDex Stock Up 51.6 %

CDXC traded up $1.80 during mid-day trading on Friday, reaching $5.29. 32,537,516 shares of the company traded hands, compared to its average volume of 450,986. The company’s fifty day moving average price is $3.48 and its 200-day moving average price is $3.22. The stock has a market capitalization of $401.67 million, a P/E ratio of -242.50 and a beta of 1.86. ChromaDex has a 52-week low of $1.32 and a 52-week high of $5.62.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.